Cargando…
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established. Methods....
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875045/ https://www.ncbi.nlm.nih.gov/pubmed/20508862 http://dx.doi.org/10.1093/ndtplus/sfq068 |
_version_ | 1782181543722090496 |
---|---|
author | Hernández, Ángel Alonso Moreso, Francesc Bayés, Beatriz Lauzurica, Ricardo Sánz-Guajardo, Dámaso Gómez-Huertas, Ernesto Pereira, Porfirio Paul, Javier Crespo, Josep Amenábar, Juan J. Oliver, Juan Serón, Daniel |
author_facet | Hernández, Ángel Alonso Moreso, Francesc Bayés, Beatriz Lauzurica, Ricardo Sánz-Guajardo, Dámaso Gómez-Huertas, Ernesto Pereira, Porfirio Paul, Javier Crespo, Josep Amenábar, Juan J. Oliver, Juan Serón, Daniel |
author_sort | Hernández, Ángel Alonso |
collection | PubMed |
description | Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established. Methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the present study. Only adult (≥18 years) recipients of a single kidney transplant functioning at the end of the first year were considered. A total of 4842 patients with clinical data about ACEI/ARB therapy were included. Results. During the initial 2 years after transplant, ACEI/ARB were less frequently used in the 1990 and 1994 cohorts than in 1998 and 2002 (15.1%, 24.6%, 33.5% and 45.1%, respectively; P < 0.001). During the first year, a total of 1063 patients (22.8%) received ACEI/ARB treatment, and graft survival (50.0% for treated patients and 51.4% for untreated, P = ns), death-censored graft survival (60.6% versus 63.5%, P = ns) and patient survival (68.8% versus 66.6%, P = ns) were not different. During the initial 2 years, 1472 patients (31.4%) received treatment with ACEI/ARB, and graft survival tended to be higher in treated patients (54.4% and 50.9%, P = 0.063). Since there was an interaction between ACEI/ARB treatment and year of transplant, graft survival was analysed in each cohort. Cox regression analysis including the propensity score for ACEI/ARB treatment showed an association between ACEI/ARB treatment and graft survival in the 2002 cohort (relative risk 0.36 and 95% confidence interval 0.17–0.75, P = 0.007). Death-censored graft survival (63.8% versus 63.1%, P = ns) and patient survival (68.1% and 66.5%, P = ns) were not significantly different. Conclusions. The use of ACEI/ARB during the initial 2 years after transplantation was associated with a better graft survival, but this effect was only observed in the 2002 cohort. |
format | Text |
id | pubmed-2875045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28750452010-06-01 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain Hernández, Ángel Alonso Moreso, Francesc Bayés, Beatriz Lauzurica, Ricardo Sánz-Guajardo, Dámaso Gómez-Huertas, Ernesto Pereira, Porfirio Paul, Javier Crespo, Josep Amenábar, Juan J. Oliver, Juan Serón, Daniel NDT Plus Original Article Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established. Methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the present study. Only adult (≥18 years) recipients of a single kidney transplant functioning at the end of the first year were considered. A total of 4842 patients with clinical data about ACEI/ARB therapy were included. Results. During the initial 2 years after transplant, ACEI/ARB were less frequently used in the 1990 and 1994 cohorts than in 1998 and 2002 (15.1%, 24.6%, 33.5% and 45.1%, respectively; P < 0.001). During the first year, a total of 1063 patients (22.8%) received ACEI/ARB treatment, and graft survival (50.0% for treated patients and 51.4% for untreated, P = ns), death-censored graft survival (60.6% versus 63.5%, P = ns) and patient survival (68.8% versus 66.6%, P = ns) were not different. During the initial 2 years, 1472 patients (31.4%) received treatment with ACEI/ARB, and graft survival tended to be higher in treated patients (54.4% and 50.9%, P = 0.063). Since there was an interaction between ACEI/ARB treatment and year of transplant, graft survival was analysed in each cohort. Cox regression analysis including the propensity score for ACEI/ARB treatment showed an association between ACEI/ARB treatment and graft survival in the 2002 cohort (relative risk 0.36 and 95% confidence interval 0.17–0.75, P = 0.007). Death-censored graft survival (63.8% versus 63.1%, P = ns) and patient survival (68.1% and 66.5%, P = ns) were not significantly different. Conclusions. The use of ACEI/ARB during the initial 2 years after transplantation was associated with a better graft survival, but this effect was only observed in the 2002 cohort. Oxford University Press 2010-06 /pmc/articles/PMC2875045/ /pubmed/20508862 http://dx.doi.org/10.1093/ndtplus/sfq068 Text en © The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. http://creativecommons.org/licenses/by-nc/2.5 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Hernández, Ángel Alonso Moreso, Francesc Bayés, Beatriz Lauzurica, Ricardo Sánz-Guajardo, Dámaso Gómez-Huertas, Ernesto Pereira, Porfirio Paul, Javier Crespo, Josep Amenábar, Juan J. Oliver, Juan Serón, Daniel Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain |
title | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain |
title_full | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain |
title_fullStr | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain |
title_full_unstemmed | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain |
title_short | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain |
title_sort | angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in spain |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875045/ https://www.ncbi.nlm.nih.gov/pubmed/20508862 http://dx.doi.org/10.1093/ndtplus/sfq068 |
work_keys_str_mv | AT hernandezangelalonso angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT moresofrancesc angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT bayesbeatriz angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT lauzuricaricardo angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT sanzguajardodamaso angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT gomezhuertasernesto angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT pereiraporfirio angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT pauljavier angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT crespojosep angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT amenabarjuanj angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT oliverjuan angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain AT serondaniel angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain |